Seoul, Sept. 24 -- South Korea's Celltrion Inc. has signed an agreement to acquire Eli Lilly and Company's U.S. biopharmaceutical manufacturing facility, eliminating its tariff-related risks in the U.S. market. The purchase price was USD 330 million, as per a report by Pulse, the English service of Maeil Business Newspaper Korea.

The acquisition price is around 460 billion won (USD 330 million), with total investment, including planned expansion, expected to reach 1.4 trillion won (USD 1.008 billion).

The report stated that Celltrion, on Tuesday, announced its U.S. subsidiary signed a contract on Saturday to acquire 100 per cent of the Branchburg, New Jersey biopharmaceutical production facility owned by Imclone Systems Holdings, a subs...